 Olivia Irby
Concepts (131)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Systemic Inflammatory Response Syndrome | 10 | 2023 | 63 | 1.080 |
Why?
| | Hospitalization | 19 | 2025 | 749 | 1.070 |
Why?
| | Child | 38 | 2026 | 7379 | 0.830 |
Why?
| | Status Asthmaticus | 1 | 2022 | 6 | 0.730 |
Why?
| | Hypokalemia | 1 | 2022 | 9 | 0.720 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2023 | 305 | 0.580 |
Why?
| | Intensive Care Units, Pediatric | 5 | 2026 | 158 | 0.530 |
Why?
| | Adolescent | 23 | 2026 | 6907 | 0.520 |
Why?
| | Critical Illness | 5 | 2026 | 316 | 0.450 |
Why?
| | Factor Xa | 1 | 2014 | 7 | 0.430 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2025 | 37 | 0.430 |
Why?
| | Intensive Care Units | 6 | 2025 | 243 | 0.420 |
Why?
| | Heparin | 1 | 2014 | 86 | 0.400 |
Why?
| | Child, Hospitalized | 3 | 2022 | 33 | 0.400 |
Why?
| | Infant | 14 | 2025 | 3805 | 0.390 |
Why?
| | Child, Preschool | 14 | 2026 | 4162 | 0.390 |
Why?
| | Humans | 42 | 2026 | 53230 | 0.370 |
Why?
| | Case-Control Studies | 9 | 2026 | 1212 | 0.350 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2023 | 64 | 0.350 |
Why?
| | Influenza, Human | 2 | 2022 | 88 | 0.350 |
Why?
| | Thrombosis | 1 | 2014 | 250 | 0.350 |
Why?
| | Anticoagulants | 1 | 2014 | 280 | 0.340 |
Why?
| | United States | 15 | 2026 | 5409 | 0.340 |
Why?
| | Nervous System Diseases | 2 | 2023 | 93 | 0.330 |
Why?
| | Vaccines, Synthetic | 4 | 2022 | 21 | 0.320 |
Why?
| | Female | 21 | 2026 | 28782 | 0.250 |
Why?
| | Vaccination | 6 | 2023 | 310 | 0.250 |
Why?
| | Retrospective Studies | 8 | 2026 | 6819 | 0.240 |
Why?
| | Patient Admission | 1 | 2025 | 81 | 0.230 |
Why?
| | Male | 18 | 2026 | 27435 | 0.220 |
Why?
| | Educational Measurement | 1 | 2026 | 202 | 0.210 |
Why?
| | Antiviral Agents | 1 | 2025 | 179 | 0.210 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2022 | 83 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 238 | 0.210 |
Why?
| | Immunocompromised Host | 1 | 2024 | 124 | 0.200 |
Why?
| | Meningitis, Aseptic | 1 | 2023 | 2 | 0.200 |
Why?
| | Infant, Newborn | 6 | 2025 | 2913 | 0.200 |
Why?
| | Connective Tissue Diseases | 1 | 2023 | 20 | 0.190 |
Why?
| | Guillain-Barre Syndrome | 1 | 2023 | 13 | 0.190 |
Why?
| | Interferon Type I | 1 | 2022 | 28 | 0.190 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 18 | 0.190 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 82 | 0.190 |
Why?
| | Tachycardia, Supraventricular | 1 | 2022 | 36 | 0.180 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2022 | 4 | 0.180 |
Why?
| | Influenza Vaccines | 1 | 2022 | 35 | 0.180 |
Why?
| | Coinfection | 1 | 2022 | 41 | 0.180 |
Why?
| | Albuterol | 1 | 2022 | 54 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 73 | 0.170 |
Why?
| | Young Adult | 6 | 2024 | 4511 | 0.160 |
Why?
| | Multiple Organ Failure | 1 | 2020 | 51 | 0.160 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 107 | 0.160 |
Why?
| | Patient Discharge | 4 | 2022 | 325 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2021 | 236 | 0.150 |
Why?
| | Asthma | 1 | 2022 | 319 | 0.140 |
Why?
| | Aftercare | 3 | 2022 | 73 | 0.140 |
Why?
| | Patient Acuity | 3 | 2022 | 17 | 0.130 |
Why?
| | Stroke | 1 | 2023 | 520 | 0.130 |
Why?
| | Prospective Studies | 4 | 2024 | 2411 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 622 | 0.130 |
Why?
| | Pregnancy | 4 | 2023 | 2608 | 0.110 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 53 | 0.110 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 1723 | 0.110 |
Why?
| | Whole Blood Coagulation Time | 1 | 2014 | 6 | 0.110 |
Why?
| | Pandemics | 3 | 2025 | 595 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 1557 | 0.100 |
Why?
| | Propensity Score | 2 | 2026 | 170 | 0.100 |
Why?
| | Seasons | 2 | 2023 | 92 | 0.090 |
Why?
| | Adult | 6 | 2024 | 14534 | 0.090 |
Why?
| | Oxygen | 1 | 2014 | 338 | 0.090 |
Why?
| | Risk Factors | 3 | 2026 | 4017 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2024 | 457 | 0.080 |
Why?
| | Mothers | 2 | 2023 | 269 | 0.080 |
Why?
| | Body Mass Index | 2 | 2025 | 717 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2024 | 1133 | 0.080 |
Why?
| | Disease Progression | 2 | 2023 | 880 | 0.080 |
Why?
| | Length of Stay | 2 | 2025 | 684 | 0.070 |
Why?
| | Logistic Models | 2 | 2022 | 947 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2025 | 5595 | 0.070 |
Why?
| | Age Factors | 2 | 2022 | 1136 | 0.070 |
Why?
| | Hospitals, Pediatric | 2 | 2022 | 243 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2025 | 119 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2023 | 4 | 0.050 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2023 | 12 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2026 | 774 | 0.050 |
Why?
| | Crowding | 1 | 2023 | 15 | 0.050 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2023 | 2 | 0.050 |
Why?
| | Receptor, Notch1 | 1 | 2023 | 5 | 0.050 |
Why?
| | NF-kappa B p52 Subunit | 1 | 2022 | 6 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2022 | 15 | 0.050 |
Why?
| | Family Characteristics | 1 | 2023 | 60 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2023 | 73 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 2 | 0.050 |
Why?
| | Immunoassay | 1 | 2022 | 23 | 0.050 |
Why?
| | Influenza B virus | 1 | 2022 | 6 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2022 | 44 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2023 | 83 | 0.050 |
Why?
| | Neutralization Tests | 1 | 2022 | 26 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 122 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2022 | 31 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2025 | 293 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 28 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2022 | 18 | 0.050 |
Why?
| | Autoantibodies | 1 | 2022 | 120 | 0.050 |
Why?
| | Life Support Care | 1 | 2022 | 18 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2022 | 98 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2022 | 25 | 0.040 |
Why?
| | Research Design | 1 | 2024 | 373 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 109 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 18 | 0.040 |
Why?
| | Immunomodulation | 1 | 2021 | 36 | 0.040 |
Why?
| | Inpatients | 1 | 2023 | 208 | 0.040 |
Why?
| | NF-kappa B | 1 | 2022 | 327 | 0.040 |
Why?
| | Shock | 1 | 2021 | 33 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2022 | 729 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 238 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 391 | 0.040 |
Why?
| | Arkansas | 1 | 2026 | 2068 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 405 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2023 | 287 | 0.040 |
Why?
| | Stroke Volume | 1 | 2021 | 150 | 0.040 |
Why?
| | Comorbidity | 1 | 2022 | 638 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 640 | 0.040 |
Why?
| | Critical Care | 1 | 2021 | 215 | 0.040 |
Why?
| | Registries | 1 | 2022 | 652 | 0.040 |
Why?
| | Inflammation | 1 | 2023 | 652 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1038 | 0.030 |
Why?
| | Time Factors | 1 | 2022 | 2991 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 40 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2014 | 50 | 0.030 |
Why?
| | Obesity | 1 | 2022 | 1204 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2014 | 132 | 0.030 |
Why?
|
|
Irby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|